Filana Therapeutics (FLNA) Net Cash Flow (2010 - 2026)

Filana Therapeutics has reported Net Cash Flow for 17 years, with the latest figure at -$3.8 million in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 22.46% year-over-year to -$3.8 million in Q2 2026; TTM through Jun 2026 was -$29.7 million, a 68.69% increase from a year earlier, with the FY2025 full-year figure at -$33.1 million, down 545.28% from the prior year.
• Net Cash Flow was -$3.8 million for Q2 2026 at Filana Therapeutics, up from -$9.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $83.1 million in Q2 2024, with the low at -$60.4 million in Q4 2024.
• Average Net Cash Flow over 5 years is -$8.4 million, with a median of -$11.9 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow jumped 536.65% in 2024, then plunged 470.79% in 2025.
• Over 5 years, Net Cash Flow stood at $26.4 million in 2022, then sank by 180.5% to -$21.2 million in 2023, then sank by 184.57% to -$60.4 million in 2024, then soared by 82.4% to -$10.6 million in 2025, then soared by 63.78% to -$3.8 million in 2026.
• The last three Net Cash Flow figures came in at -$3.8 million (Q2 2026), -$9.0 million (Q1 2026), and -$10.6 million (Q4 2025), per Business Quant data.